Artificial intelligence is moving further into drug discovery with the launch of Charm Therapeutics Ltd., which arrives on the scene with a $50 million series A round.
LONDON – The Google artificial intelligence company Deepmind has developed an algorithm that can predict the 3D structure of a protein from its amino acid sequence, making it possible to solve the structures of proteins, such as G-protein coupled receptors (GPCRs), which are a mainstay of drug targeting but whose structure is challenging to determine with current methods.
